NASDAQ: AWH - Aspira Women's Health

Yield per half year: -16.23%
Sector: Healthcare

Company Analysis Aspira Women's Health

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (2.89 $) is less than fair price (4.73 $)
  • The company's current efficiency (ROE=705.71%) is higher than the sector average (ROE=9.61%)

Disadvantages

  • Dividends (0%) are below the sector average (0.5491%).
  • The stock's return over the last year (-43.44%) is lower than the sector average (-33.16%).
  • Current debt level 45.54% has increased over 5 years from 1.66%.

Similar companies

Amgen

Alexion

ABIOMED

Gilead Sciences

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Aspira Women's Health Healthcare Index
7 days 251.6% 1% 0.7%
90 days 78.4% -48.3% 7.3%
1 year -43.4% -33.2% 33.6%

AWH vs Sector: Aspira Women's Health has significantly underperformed the "Healthcare" sector by -10.28% over the past year.

AWH vs Market: Aspira Women's Health has significantly underperformed the market by -77.01% over the past year.

Slightly volatile price: AWH is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.

Long period: AWH with weekly volatility of -0.8355% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 2.92

3.2. Revenue

EPS -1.81
ROE 705.71%
ROA -266.53%
ROIC 0%
Ebitda margin -203.77%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (2.89 $) is lower than the fair price (4.73 $).

Price significantly below the fair price: The current price (2.89 $) is 63.7% lower than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).

P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.05).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (-11.28) is lower than that of the sector as a whole (4.82).

P/BV vs Market: The company's P/BV (-11.28) is lower than that of the market as a whole (3.1).

4.4. P/S

P/S vs Sector: The company's P/S indicator (2.92) is lower than that of the sector as a whole (33.76).

P/S vs Market: The company's P/S indicator (2.92) is lower than that of the market as a whole (10.14).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-1.44) is higher than that of the sector as a whole (-22.12).

EV/Ebitda vs Market: The company's EV/Ebitda (-1.44) is lower than that of the market as a whole (19.1).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 1.91% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1.91%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).

5.4. ROE

ROE vs Sector: The company's ROE (705.71%) is higher than that of the sector as a whole (9.61%).

ROE vs Market: The company's ROE (705.71%) is higher than that of the market as a whole (10.87%).

5.5. ROA

ROA vs Sector: The company's ROA (-266.53%) is lower than that of the sector as a whole (0.3359%).

ROA vs Market: The company's ROA (-266.53%) is lower than that of the market as a whole (6.5%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).

6. Finance

6.1. Assets and debt

Debt level: (45.54%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 1.66% to 45.54%.

Excess of debt: The debt is not covered by net income, percentage -17.09%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5491%.

7.2. Stability and increase in payments

Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.71.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Aspira Women's Health

9.1. Stocks forum - Latest comments

4 february 2022 05:29
ПЛЮСЫ 1. Увеличении выручки на 42% за последний год. 2. Краткосрочные активы ($47.2M) превышают его краткосрочные обязательства ($6,4 МЛН). 3. Краткосрочные активы AWH ($47,2 млн) превышают его долгосрочные обязательства ($3,1 МЛН). 4. AWH имеет больше денежных средств, чем его общий долг. 5. Отношение долга к собственному капиталу AWH за последние 5 лет сократилось с 29,3% до 7,7%. 6. Прогнозируется, что выручка AWH (52,4% в год) будет расти быстрее, чем на 20% в год. 7. Торгуется ниже нашей оценки справедливая стоимость ($10.79) МИНУСЫ 1. Общее количество акций в обращении выросло на 7,2%. 2. Акционеры Aspira Women's Health потеряли 86% 3. Прогнозируется, что AWH останется убыточным в течение следующих 3 лет.

9.3. Comments